Literature DB >> 18635705

Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis.

S Cader1, J Palace, P M Matthews.   

Abstract

The aim of this study is to define mechanisms underlying the pharmacological effects of brain cholinesterase inhibition on cognitive function in patients with multiple sclerosis (MS). Both a Stroop task and an N-back task were used to probe the changes in brain activity using functional magnetic resonance imaging (fMRI) in a single (investigator)-blind, crossover treatment design studying 15 patients with multiple sclerosis (12 relapsing remitting, 3 secondary progressive) taking rivastigmine (4.5 mg po bid) and domperidone (10 mg po qd) or domperidone alone. Administration of rivastigmine increased Stroop functional magnetic resonance imaging activation in the right inferior frontal gyrus for the Stroop task (P < 0.05, corrected). Incremental functional magnetic resonance imaging activation with progressively greater N-back task difficulty was enhanced by rivastigmine in prefrontal and parietal cortical regions (P < 0.01, ANOVA). Functional connectivity analysis of the N-back functional magnetic resonance imaging data based on correlations between pair-wise interregional activations showed increased connectivity between left to right prefrontal, anterior cingulate to left prefrontal and right parietal to right prefrontal regions with rivastigmine (P < 0.05, corrected). Although there were no statistically significant changes in the neuropsychological task performance with rivastigmine in this small study, 11 of 15 patients showed improvements, whereas only 4 of 15 patients showed decline in performance (P = 0.07). With regard to the previous data, these findings suggest different patterns of brain response to lower dose acute and higher dose chronic administration of rivastigmine in patients with multiple sclerosis. They showed that rivastigmine enhances the prefrontal function and alters the functional connectivity associated with cognition. We interpret this as evidence for greater efficiency of brain information transfer that should increase confidence in a potentially beneficial clinical therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635705     DOI: 10.1177/0269881108093271

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  13 in total

Review 1.  Functional brain imaging of nicotinic effects on higher cognitive processes.

Authors:  Paul A Newhouse; Alexandra S Potter; Julie A Dumas; Christiane M Thiel
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

2.  Cognitive impairment and MS: searching for effective therapies.

Authors:  Vijayshree Yadav; Dennis N Bourdette
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

3.  Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study.

Authors:  Ekaterina Dobryakova; Maria Assunta Rocca; Paola Valsasina; Angelo Ghezzi; Bruno Colombo; Vittorio Martinelli; Giancarlo Comi; John DeLuca; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2016-03-09       Impact factor: 5.038

4.  Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study.

Authors:  Maria A Rocca; Paola Valsasina; Hanneke E Hulst; Khaled Abdel-Aziz; Christian Enzinger; Antonio Gallo; Debora Pareto; Gianna Riccitelli; Nils Muhlert; Olga Ciccarelli; Frederik Barkhof; Franz Fazekas; Gioacchino Tedeschi; Maria J Arévalo; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2014-07-18       Impact factor: 5.038

Review 5.  The contribution of MRI in assessing cognitive impairment in multiple sclerosis.

Authors:  M Filippi; M A Rocca; R H B Benedict; J DeLuca; J J G Geurts; S A R B Rombouts; M Ron; G Comi
Journal:  Neurology       Date:  2010-12-07       Impact factor: 9.910

Review 6.  Advanced MRI in multiple sclerosis: current status and future challenges.

Authors:  Robert J Fox; Erik Beall; Pallab Bhattacharyya; Jacqueline T Chen; Ken Sakaie
Journal:  Neurol Clin       Date:  2011-05       Impact factor: 3.806

Review 7.  Mind the gap: from neurons to networks to outcomes in multiple sclerosis.

Authors:  Declan T Chard; Adnan A S Alahmadi; Bertrand Audoin; Thalis Charalambous; Christian Enzinger; Hanneke E Hulst; Maria A Rocca; Àlex Rovira; Jaume Sastre-Garriga; Menno M Schoonheim; Betty Tijms; Carmen Tur; Claudia A M Gandini Wheeler-Kingshott; Alle Meije Wink; Olga Ciccarelli; Frederik Barkhof
Journal:  Nat Rev Neurol       Date:  2021-01-12       Impact factor: 42.937

8.  Novel information on the non-neuronal cholinergic system in orthopedics provides new possible treatment strategies for inflammatory and degenerative diseases.

Authors:  Sture Forsgren; Håkan Alfredson; Dennis Bjur; Solbritt Rantapää-Dahlqvist; Orjan Norrgård; Tore Dalén; Patrik Danielson
Journal:  Orthop Rev (Pavia)       Date:  2009-06-30

Review 9.  Network collapse and cognitive impairment in multiple sclerosis.

Authors:  Menno M Schoonheim; Kim A Meijer; Jeroen J G Geurts
Journal:  Front Neurol       Date:  2015-04-14       Impact factor: 4.003

Review 10.  Neuroplasticity and functional recovery in multiple sclerosis.

Authors:  Valentina Tomassini; Paul M Matthews; Alan J Thompson; Daniel Fuglø; Jeroen J Geurts; Heidi Johansen-Berg; Derek K Jones; Maria A Rocca; Richard G Wise; Frederik Barkhof; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2012-11-05       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.